Acne Vulgaris Market Poised for Growth as Emerging Therapies Reshape Treatment Landscape Through 2034, Reports DelveInsight

DelveInsight's latest report, "Acne Vulgaris Market Insights, Epidemiology, and Market Forecast - 2034," delivers a comprehensive analysis of the Acne Vulgaris landscape, covering historical and projected epidemiology, current treatment practices, and evolving market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Gain exclusive access to in-depth market dynamics, emerging therapies, and pipeline advancements in the Acne Vulgaris space. Download the full report here: Acne Vulgaris Market Size - https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Acne Vulgaris Market Report
• In September 2025, Vanda Pharmaceuticals launched a Phase II, multicenter, randomized, double-blind, placebo-controlled clinical study to assess the safety, efficacy, and pharmacokinetics of imsidolimab in both adolescent and adult Acne Vulgaris patients. The trial also investigates the immune response to the drug.
• Approximately 140.2 million prevalent cases of Acne Vulgaris were reported across the 7MM in 2023, with nearly 69.5 million cases in the US alone. These figures are projected to grow steadily throughout the forecast period.
• Gender-based analysis indicates that females accounted for 63% of diagnosed prevalent cases across the 7MM.
• By severity, moderate acne represented the largest diagnosed population (45%) in 2023, while severe cases comprised about 10%.
• Leading Acne Vulgaris companies include Galderma Labs, Ortho Dermatologics, Bausch Health, Timber Pharmaceuticals, BioPharmX, Botanix Pharmaceuticals, Kintor Pharma, among others.
• Key Acne Vulgaris emerging therapies include B244, SB204, DMT310, BTX 1503, and several additional candidates.

Stay competitive with actionable insights into market performance, therapeutic advancements, and strategic opportunities. Access further details here: Acne Vulgaris Treatment Market Size - https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Acne Vulgaris Epidemiology Segmentation Covered in the Report (7MM)
• Total Acne Vulgaris Prevalent Cases
• Acne Vulgaris Diagnosed Prevalent Cases
• Acne Vulgaris Severity-Based Diagnosed Cases
• Gender-Specific Diagnosed Cases
• Age-Specific Diagnosed Cases

Download the report to explore the key factors influencing epidemiology trends: Acne Vulgaris Prevalence - https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Marketed Therapies for Acne Vulgaris
AKLIEF (Trifarotene) - Galderma S.A.
A fourth-generation topical retinoid approved by the FDA for patients aged ≥9 years. Trifarotene selectively targets RAR-γ receptors-the most abundant retinoic acid receptors in the skin-offering enhanced specificity and improved outcomes. It demonstrates early and sustained efficacy across facial and truncal acne, with mild, manageable side effects such as irritation and pruritus.

AMZEEQ (Minocycline) - Journey Medical Corp./Vyne Therapeutics
Approved in 2019, AMZEEQ is a topical foam formulation of minocycline for moderate-to-severe inflammatory acne in patients aged ≥9 years. Leveraging Foamix's MST technology, the foam provides targeted delivery with broad dermatological utility, including use in rosacea.

ARAZLO (Tazarotene) - Bausch Health/Ortho Dermatologics
A 0.045% tazarotene lotion designed to minimize irritation through an optimized polymeric emulsion technology and the inclusion of moisturizing agents. Approved for patients aged ≥9 years, it offers effective acne management with an improved tolerability profile.

Promising Acne Vulgaris Emerging Therapies
SB204 - Pelthos Therapeutics
A nitric oxide-based topical monotherapy targeting the multifactorial nature of acne through anti-inflammatory and antibacterial mechanisms.

B244 - AOBiome
A novel microbiome-restoring topical treatment containing Nitrosomonas eutropha, designed to modulate inflammation and rebalance the skin ecosystem.

DMT310 - Dermata Therapeutics
A first-in-class biological treatment derived from Spongilla lacustris, targeting IL-17 mediated inflammation. Currently in Phase III development for Acne Vulgaris.

Explore next-generation treatment options and pipeline updates: Acne Vulgaris Market Drivers and Barriers - https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Acne Vulgaris Market Outlook
Managing Acne Vulgaris requires a multi-tiered approach combining lifestyle modifications, topical regimens, and systemic therapies. Market growth is propelled by increasing disease prevalence, rising consumer focus on skincare, and expanding therapeutic alternatives. Current treatment categories include keratolytics (salicylic acid, azelaic acid), oral antibiotics (tetracycline, doxycycline), retinoids (isotretinoin), and hormonal agents (spironolactone).

Scope of the Acne Vulgaris Market Report
• Geographies Covered: 7MM
• Study Period: 2020-2034
• Key Acne Vulgaris Companies: Galderma Labs, Ortho Dermatologics, Bausch Health, Timber Pharmaceuticals, BioPharmX, Botanix Pharmaceuticals, Kintor Pharma, and others
• Key Acne Vulgaris Therapies: B244, SB204, DMT310, BTX 1503, among others
• Assessment Areas: Marketed & Emerging Therapies, Market Dynamics, Unmet Needs, KOL Insights, Reimbursement Landscape

Learn more about ongoing trials, competitive intelligence, and evolving market opportunities: Acne Vulgaris Clinical Trials Analysis - https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.